Cargando…
Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes
AIM: Multiple studies support the efficacy of combining a glucagon‐like peptide 1 receptor agonist (GLP‐1RA) with basal insulin in people with type 2 diabetes inadequately controlled on dual/triple oral therapy. Fixed‐ratio combinations of basal insulin + GLP‐1RA represent a further advance to facil...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314929/ https://www.ncbi.nlm.nih.gov/pubmed/35257461 http://dx.doi.org/10.1111/dom.14688 |